GlassScriptPhysician profile
Ladonna K Maxwell
NPI 1417037292
$1,878.65
in general payments reported to CMS, 2019-2025
11 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.80 · 2022: $144 · 2023: $393 · 2024: $222 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $749.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $267.57 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.20 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $171.50 | 2021-2025 | Invega |
| Novo Nordisk INC | $151.68 | 2025 | Ozempic, Wegovy |
| Organogenesis INC. | $130.00 | 2025 | Puraply Wound Matrix, Apligraf, Affinity |
| Amgen INC. | $47.40 | 2025 | Krystexxa |
| Pfizer INC. | $39.13 | 2021-2023 | |
| Corcept Therapeutics | $37.16 | 2024 | Korlym |
| Neurocrine Biosciences, INC. | $29.79 | 2025 | |
| Glaxosmithkline, LLC. | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ladonna Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.